Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Rectal Neoplasms 1Lymphoma, T-Cell, Peripheral 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 25Oxaliplatin 24Irinotecan 24Leucovorin 23Bevacizumab 23Capecitabine 18Cetuximab 15Radiotherapy 6Gene Expression Profiling 5regorafenib 4Immunohistochemistry 4Gemcitabine 4Folfox protocol 4Colonoscopy 4Cisplatin 4Celecoxib 4Amplified Fragment Length Polymorphism Analysis 4Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Polymerase Chain Reaction 3Nivolumab 3Mitomycin 3Doxorubicin 3Cyclophosphamide 3Cholecalciferol 3Biopsy 3Aspirin 3sargramostim 2pembrolizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colonic Neoplasms × Immunoconjugates × Clear all
NCT01605318 2024-01-24

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Gilead Sciences

Phase 1/2 Terminated
92 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡